Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of “Moderate Buy” by Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO) has been given an average recommendation of “Moderate Buy” by the eight analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $26.3333.

A number of analysts recently issued reports on ANRO shares. BTIG Research assumed coverage on shares of Alto Neuroscience in a research note on Monday, November 17th. They issued a “buy” rating and a $27.00 price target for the company. Robert W. Baird boosted their target price on shares of Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Wall Street Zen upgraded shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. HC Wainwright lifted their price target on Alto Neuroscience from $10.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 24th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th.

Alto Neuroscience Trading Up 3.4%

Shares of ANRO opened at $17.00 on Monday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42. Alto Neuroscience has a one year low of $1.60 and a one year high of $20.91. The stock has a 50-day moving average price of $16.78 and a 200 day moving average price of $10.72. The company has a market capitalization of $528.13 million, a P/E ratio of -7.42 and a beta of 2.79.

Hedge Funds Weigh In On Alto Neuroscience

A number of hedge funds have recently added to or reduced their stakes in the business. Torren Management LLC acquired a new stake in shares of Alto Neuroscience during the fourth quarter worth $62,000. Bank of Montreal Can bought a new stake in shares of Alto Neuroscience during the 2nd quarter valued at about $25,000. Ground Swell Capital LLC acquired a new stake in Alto Neuroscience during the second quarter worth about $27,000. Vanguard Personalized Indexing Management LLC bought a new position in Alto Neuroscience in the second quarter worth about $33,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Alto Neuroscience in the fourth quarter valued at approximately $304,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.